|
|
drug_name
|
event_name
|
drug_id
|
event_id
|
drug_and_event_name
|
|
3
|
Chlorthalidone
|
Chronic bronchitis
|
1395058
|
255841
|
Chlorthalidone & Chronic bronchitis
|
## Chronograph ##

## Basic demographic table##
|
|
1: DEC cohort
|
n
|
Percentage
|
|
2: Drug cohort
|
n
|
Percentage
|
|
3: Event cohort
|
n
|
Percentage
|
|
4: All drugs cohort
|
n
|
Percentage
|
|
|
Total
|
101
|
100
|
|
Total
|
1000
|
100
|
|
Total
|
721
|
100
|
|
Total
|
1000
|
100
|
|
Sex
|
gender = FEMALE
|
56
|
55
|
Sex
|
gender = FEMALE
|
594
|
59
|
Sex
|
gender = FEMALE
|
426
|
59
|
Sex
|
gender = FEMALE
|
546
|
55
|
|
|
gender = MALE
|
45
|
45
|
|
gender = MALE
|
406
|
41
|
|
gender = MALE
|
295
|
41
|
|
gender = MALE
|
454
|
45
|
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
Age
|
(0,20]
|
0
|
0
|
|
|
(20,30]
|
0
|
0
|
|
(20,30]
|
4
|
0
|
|
(20,30]
|
2
|
0
|
|
(20,30]
|
6
|
1
|
|
|
(30,40]
|
6
|
6
|
|
(30,40]
|
19
|
2
|
|
(30,40]
|
17
|
2
|
|
(30,40]
|
13
|
1
|
|
|
(40,50]
|
3
|
3
|
|
(40,50]
|
66
|
7
|
|
(40,50]
|
24
|
3
|
|
(40,50]
|
44
|
4
|
|
|
(50,60]
|
10
|
10
|
|
(50,60]
|
75
|
8
|
|
(50,60]
|
38
|
5
|
|
(50,60]
|
58
|
6
|
|
|
(60,70]
|
26
|
26
|
|
(60,70]
|
201
|
20
|
|
(60,70]
|
156
|
22
|
|
(60,70]
|
222
|
22
|
|
|
(70,80]
|
33
|
33
|
|
(70,80]
|
340
|
34
|
|
(70,80]
|
254
|
35
|
|
(70,80]
|
390
|
39
|
|
|
(80,90]
|
19
|
19
|
|
(80,90]
|
241
|
24
|
|
(80,90]
|
178
|
25
|
|
(80,90]
|
221
|
22
|
|
|
(90,110]
|
4
|
4
|
|
(90,110]
|
54
|
5
|
|
(90,110]
|
52
|
7
|
|
(90,110]
|
46
|
5
|
|
|
Median
|
72
|
IQR=(66, 80)
|
|
Median
|
74
|
IQR=(67, 82)
|
|
Median
|
75
|
IQR=(69, 83)
|
|
Median
|
74
|
IQR=(68, 81)
|
## Gender distribution ##
## DEC vs. drug ##
|
Characteristic
|
% (n = 101)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 101)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
3.0
|
2.1
|
-0.06
|
|
25 - 29
|
0
|
0.1
|
0.04
|
Visual system disorder
|
46.5
|
35.5
|
-0.23
|
|
30 - 34
|
1.0
|
1.0
|
0.00
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
5.0
|
0.9
|
-0.24
|
Atrial fibrillation
|
40.6
|
26.2
|
-0.31
|
|
40 - 44
|
0
|
2.1
|
0.21
|
Cerebrovascular disease
|
18.8
|
9.1
|
-0.28
|
|
45 - 49
|
3.0
|
4.2
|
0.07
|
Coronary arteriosclerosis
|
41.6
|
30.3
|
-0.24
|
|
50 - 54
|
3.0
|
3.3
|
0.02
|
Heart disease
|
82.2
|
58.4
|
-0.54
|
|
55 - 59
|
5.0
|
4.2
|
-0.04
|
Heart failure
|
42.6
|
24.1
|
-0.40
|
|
60 - 64
|
5.0
|
3.4
|
-0.08
|
Ischemic heart disease
|
15.8
|
15.5
|
-0.01
|
|
65 - 69
|
17.8
|
13.3
|
-0.12
|
Peripheral vascular disease
|
41.6
|
26.5
|
-0.32
|
|
70 - 74
|
17.8
|
18.6
|
0.02
|
Pulmonary embolism
|
4.0
|
2.2
|
-0.10
|
|
75 - 79
|
16.8
|
15.9
|
-0.03
|
Venous thrombosis
|
8.9
|
6.9
|
-0.07
|
|
80 - 84
|
10.9
|
13.9
|
0.09
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
10.9
|
11.6
|
0.02
|
Hematologic neoplasm
|
9.9
|
7.1
|
-0.10
|
|
90 - 94
|
1.0
|
4.2
|
0.20
|
Malignant lymphoma
|
4.0
|
3.3
|
-0.04
|
|
95 - 99
|
3.0
|
2.3
|
-0.04
|
Malignant neoplasm of anorectum
|
1.0
|
1.0
|
0.00
|
|
100 - 104
|
0
|
1.0
|
0.14
|
Malignant neoplastic disease
|
41.6
|
24.4
|
-0.37
|
|
Gender: female
|
55.4
|
59.4
|
0.08
|
Malignant tumor of breast
|
7.9
|
3.3
|
-0.20
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
5.9
|
2.9
|
-0.15
|
|
Acute respiratory disease
|
27.7
|
20.9
|
-0.16
|
Malignant tumor of lung
|
4.0
|
2.5
|
-0.08
|
|
Attention deficit hyperactivity disorder
|
2.0
|
0.4
|
-0.15
|
Malignant tumor of urinary bladder
|
4.0
|
1.5
|
-0.15
|
|
Chronic liver disease
|
5.0
|
3.2
|
-0.09
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
15.8
|
9.2
|
-0.20
|
Agents acting on the renin-angiotensin system
|
77.2
|
71.3
|
-0.14
|
|
Crohn’s disease
|
0
|
0.2
|
0.06
|
Antibacterials for systemic use
|
65.3
|
49.0
|
-0.33
|
|
Dementia
|
18.8
|
11.2
|
-0.21
|
Antidepressants
|
67.3
|
60.3
|
-0.15
|
|
Depressive disorder
|
24.8
|
9.7
|
-0.41
|
Antiepileptics
|
43.6
|
33.7
|
-0.20
|
|
Diabetes mellitus
|
73.3
|
52.1
|
-0.45
|
Antiinflammatory and antirheumatic products
|
38.6
|
33.3
|
-0.11
|
|
Gastroesophageal reflux disease
|
24.8
|
13.1
|
-0.30
|
Antineoplastic agents
|
18.8
|
10.0
|
-0.25
|
|
Gastrointestinal hemorrhage
|
6.9
|
6.1
|
-0.03
|
Antipsoriatics
|
1.0
|
0.6
|
-0.04
|
|
Human immunodeficiency virus infection
|
0
|
0.3
|
0.08
|
Antithrombotic agents
|
57.4
|
47.8
|
-0.19
|
|
Hyperlipidemia
|
36.6
|
22.5
|
-0.31
|
Beta blocking agents
|
77.2
|
71.4
|
-0.13
|
|
Hypertensive disorder
|
13.9
|
4.9
|
-0.31
|
Calcium channel blockers
|
58.4
|
56.1
|
-0.05
|
|
Lesion of liver
|
7.9
|
3.6
|
-0.19
|
Diuretics
|
74.3
|
67.3
|
-0.15
|
|
Obesity
|
10.9
|
5.8
|
-0.18
|
Drugs for acid related disorders
|
63.4
|
44.7
|
-0.38
|
|
Osteoarthritis
|
62.4
|
35.0
|
-0.57
|
Drugs for obstructive airway diseases
|
49.5
|
34.9
|
-0.30
|
|
Pneumonia
|
6.9
|
4.2
|
-0.12
|
Drugs used in diabetes
|
66.3
|
54.3
|
-0.25
|
|
Psoriasis
|
4.0
|
2.0
|
-0.12
|
Immunosuppressants
|
5.0
|
4.8
|
-0.01
|
|
Renal impairment
|
40.6
|
22.6
|
-0.39
|
Lipid modifying agents
|
81.2
|
73.6
|
-0.18
|
|
Rheumatoid arthritis
|
8.9
|
5.2
|
-0.15
|
Opioids
|
39.6
|
29.5
|
-0.21
|
|
Schizophrenia
|
5.0
|
6.6
|
0.07
|
Psycholeptics
|
59.4
|
51.8
|
-0.15
|
|
Ulcerative colitis
|
0
|
0.2
|
0.06
|
Psychostimulants, agents used for adhd and nootropics
|
17.8
|
14.7
|
-0.08
|
|
Urinary tract infectious disease
|
27.7
|
19.6
|
-0.19
|
|
|
|
|
## Event vs. All ##
|
Characteristic
|
% (n = 721)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 721)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
1.9
|
1.3
|
-0.05
|
|
25 - 29
|
0.1
|
0.6
|
0.08
|
Visual system disorder
|
51.0
|
40.5
|
-0.21
|
|
30 - 34
|
0.8
|
0.9
|
0.01
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.2
|
0.4
|
-0.09
|
Atrial fibrillation
|
39.9
|
27.7
|
-0.26
|
|
40 - 44
|
1.2
|
0.9
|
-0.03
|
Cerebrovascular disease
|
15.3
|
9.4
|
-0.18
|
|
45 - 49
|
1.9
|
3.1
|
0.07
|
Coronary arteriosclerosis
|
47.4
|
29.3
|
-0.38
|
|
50 - 54
|
2.2
|
2.4
|
0.01
|
Heart disease
|
81.0
|
57.6
|
-0.52
|
|
55 - 59
|
2.9
|
3.2
|
0.02
|
Heart failure
|
40.5
|
24.2
|
-0.35
|
|
60 - 64
|
4.4
|
2.9
|
-0.08
|
Ischemic heart disease
|
25.9
|
13.5
|
-0.32
|
|
65 - 69
|
13.9
|
15.4
|
0.04
|
Peripheral vascular disease
|
44.7
|
26.0
|
-0.40
|
|
70 - 74
|
18.3
|
23.2
|
0.12
|
Pulmonary embolism
|
3.6
|
2.9
|
-0.04
|
|
75 - 79
|
17.5
|
17.8
|
0.01
|
Venous thrombosis
|
12.8
|
8.7
|
-0.13
|
|
80 - 84
|
14.3
|
13.3
|
-0.03
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.7
|
9.6
|
-0.07
|
Hematologic neoplasm
|
12.8
|
9.2
|
-0.11
|
|
90 - 94
|
5.5
|
4.0
|
-0.07
|
Malignant lymphoma
|
5.0
|
4.0
|
-0.05
|
|
95 - 99
|
3.1
|
1.9
|
-0.07
|
Malignant neoplasm of anorectum
|
1.5
|
1.7
|
0.01
|
|
100 - 104
|
0.8
|
0.4
|
-0.06
|
Malignant neoplastic disease
|
38.7
|
27.2
|
-0.25
|
|
Gender: female
|
59.1
|
54.6
|
-0.09
|
Malignant tumor of breast
|
4.9
|
3.5
|
-0.07
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
4.7
|
3.1
|
-0.08
|
|
Acute respiratory disease
|
37.9
|
21.8
|
-0.36
|
Malignant tumor of lung
|
6.5
|
4.2
|
-0.10
|
|
Attention deficit hyperactivity disorder
|
0.7
|
0.3
|
-0.06
|
Malignant tumor of urinary bladder
|
4.4
|
2.7
|
-0.09
|
|
Chronic liver disease
|
4.0
|
2.5
|
-0.09
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
19.7
|
9.6
|
-0.29
|
Agents acting on the renin-angiotensin system
|
49.4
|
0
|
-1.40
|
|
Crohn’s disease
|
1.5
|
0.4
|
-0.12
|
Antibacterials for systemic use
|
40.6
|
0
|
-1.17
|
|
Dementia
|
17.9
|
10.6
|
-0.21
|
Antidepressants
|
44.1
|
0
|
-1.26
|
|
Depressive disorder
|
14.1
|
8.3
|
-0.19
|
Antiepileptics
|
25.4
|
0
|
-0.82
|
|
Diabetes mellitus
|
71.2
|
48.2
|
-0.48
|
Antiinflammatory and antirheumatic products
|
23.4
|
0
|
-0.78
|
|
Gastroesophageal reflux disease
|
24.0
|
14.6
|
-0.24
|
Antineoplastic agents
|
15.8
|
0
|
-0.61
|
|
Gastrointestinal hemorrhage
|
9.8
|
6.1
|
-0.14
|
Antipsoriatics
|
0.6
|
0
|
-0.11
|
|
Human immunodeficiency virus infection
|
0.4
|
0.5
|
0.01
|
Antithrombotic agents
|
40.8
|
0
|
-1.17
|
|
Hyperlipidemia
|
33.1
|
25.5
|
-0.17
|
Beta blocking agents
|
43.0
|
0
|
-1.23
|
|
Hypertensive disorder
|
6.9
|
3.9
|
-0.13
|
Calcium channel blockers
|
34.8
|
0
|
-1.03
|
|
Lesion of liver
|
5.4
|
3.4
|
-0.10
|
Diuretics
|
45.5
|
0
|
-1.29
|
|
Obesity
|
9.3
|
5.4
|
-0.15
|
Drugs for acid related disorders
|
35.0
|
0
|
-1.04
|
|
Osteoarthritis
|
54.1
|
38.9
|
-0.31
|
Drugs for obstructive airway diseases
|
32.5
|
0
|
-0.98
|
|
Pneumonia
|
10.7
|
4.9
|
-0.22
|
Drugs used in diabetes
|
38.1
|
0
|
-1.11
|
|
Psoriasis
|
2.4
|
1.6
|
-0.05
|
Immunosuppressants
|
4.6
|
0
|
-0.31
|
|
Renal impairment
|
35.4
|
23.9
|
-0.25
|
Lipid modifying agents
|
47.6
|
0
|
-1.35
|
|
Rheumatoid arthritis
|
9.2
|
6.3
|
-0.11
|
Opioids
|
27.7
|
0
|
-0.88
|
|
Schizophrenia
|
8.0
|
4.0
|
-0.17
|
Psycholeptics
|
38.4
|
0
|
-1.12
|
|
Ulcerative colitis
|
0.6
|
0.3
|
-0.04
|
Psychostimulants, agents used for adhd and nootropics
|
11.2
|
0
|
-0.50
|
|
Urinary tract infectious disease
|
28.7
|
18.4
|
-0.24
|
|
|
|
|
## Drug vs. All ##
|
Characteristic
|
% (n = 721)
|
% (n = 1,000)
|
Std.Diff
|
Characteristic
|
% (n = 721)
|
% (n = 1,000)
|
Std.Diff
|
|
Age group
|
|
|
|
Viral hepatitis C
|
1.9
|
1.3
|
-0.05
|
|
25 - 29
|
0.1
|
0.6
|
0.08
|
Visual system disorder
|
51.0
|
40.5
|
-0.21
|
|
30 - 34
|
0.8
|
0.9
|
0.01
|
Medical history: Cardiovascular disease
|
|
|
|
|
35 - 39
|
1.2
|
0.4
|
-0.09
|
Atrial fibrillation
|
39.9
|
27.7
|
-0.26
|
|
40 - 44
|
1.2
|
0.9
|
-0.03
|
Cerebrovascular disease
|
15.3
|
9.4
|
-0.18
|
|
45 - 49
|
1.9
|
3.1
|
0.07
|
Coronary arteriosclerosis
|
47.4
|
29.3
|
-0.38
|
|
50 - 54
|
2.2
|
2.4
|
0.01
|
Heart disease
|
81.0
|
57.6
|
-0.52
|
|
55 - 59
|
2.9
|
3.2
|
0.02
|
Heart failure
|
40.5
|
24.2
|
-0.35
|
|
60 - 64
|
4.4
|
2.9
|
-0.08
|
Ischemic heart disease
|
25.9
|
13.5
|
-0.32
|
|
65 - 69
|
13.9
|
15.4
|
0.04
|
Peripheral vascular disease
|
44.7
|
26.0
|
-0.40
|
|
70 - 74
|
18.3
|
23.2
|
0.12
|
Pulmonary embolism
|
3.6
|
2.9
|
-0.04
|
|
75 - 79
|
17.5
|
17.8
|
0.01
|
Venous thrombosis
|
12.8
|
8.7
|
-0.13
|
|
80 - 84
|
14.3
|
13.3
|
-0.03
|
Medical history: Neoplasms
|
|
|
|
|
85 - 89
|
11.7
|
9.6
|
-0.07
|
Hematologic neoplasm
|
12.8
|
9.2
|
-0.11
|
|
90 - 94
|
5.5
|
4.0
|
-0.07
|
Malignant lymphoma
|
5.0
|
4.0
|
-0.05
|
|
95 - 99
|
3.1
|
1.9
|
-0.07
|
Malignant neoplasm of anorectum
|
1.5
|
1.7
|
0.01
|
|
100 - 104
|
0.8
|
0.4
|
-0.06
|
Malignant neoplastic disease
|
38.7
|
27.2
|
-0.25
|
|
Gender: female
|
59.1
|
54.6
|
-0.09
|
Malignant tumor of breast
|
4.9
|
3.5
|
-0.07
|
|
Medical history: General
|
|
|
|
Malignant tumor of colon
|
4.7
|
3.1
|
-0.08
|
|
Acute respiratory disease
|
37.9
|
21.8
|
-0.36
|
Malignant tumor of lung
|
6.5
|
4.2
|
-0.10
|
|
Attention deficit hyperactivity disorder
|
0.7
|
0.3
|
-0.06
|
Malignant tumor of urinary bladder
|
4.4
|
2.7
|
-0.09
|
|
Chronic liver disease
|
4.0
|
2.5
|
-0.09
|
Medication use
|
|
|
|
|
Chronic obstructive lung disease
|
19.7
|
9.6
|
-0.29
|
Agents acting on the renin-angiotensin system
|
49.4
|
0
|
-1.40
|
|
Crohn’s disease
|
1.5
|
0.4
|
-0.12
|
Antibacterials for systemic use
|
40.6
|
0
|
-1.17
|
|
Dementia
|
17.9
|
10.6
|
-0.21
|
Antidepressants
|
44.1
|
0
|
-1.26
|
|
Depressive disorder
|
14.1
|
8.3
|
-0.19
|
Antiepileptics
|
25.4
|
0
|
-0.82
|
|
Diabetes mellitus
|
71.2
|
48.2
|
-0.48
|
Antiinflammatory and antirheumatic products
|
23.4
|
0
|
-0.78
|
|
Gastroesophageal reflux disease
|
24.0
|
14.6
|
-0.24
|
Antineoplastic agents
|
15.8
|
0
|
-0.61
|
|
Gastrointestinal hemorrhage
|
9.8
|
6.1
|
-0.14
|
Antipsoriatics
|
0.6
|
0
|
-0.11
|
|
Human immunodeficiency virus infection
|
0.4
|
0.5
|
0.01
|
Antithrombotic agents
|
40.8
|
0
|
-1.17
|
|
Hyperlipidemia
|
33.1
|
25.5
|
-0.17
|
Beta blocking agents
|
43.0
|
0
|
-1.23
|
|
Hypertensive disorder
|
6.9
|
3.9
|
-0.13
|
Calcium channel blockers
|
34.8
|
0
|
-1.03
|
|
Lesion of liver
|
5.4
|
3.4
|
-0.10
|
Diuretics
|
45.5
|
0
|
-1.29
|
|
Obesity
|
9.3
|
5.4
|
-0.15
|
Drugs for acid related disorders
|
35.0
|
0
|
-1.04
|
|
Osteoarthritis
|
54.1
|
38.9
|
-0.31
|
Drugs for obstructive airway diseases
|
32.5
|
0
|
-0.98
|
|
Pneumonia
|
10.7
|
4.9
|
-0.22
|
Drugs used in diabetes
|
38.1
|
0
|
-1.11
|
|
Psoriasis
|
2.4
|
1.6
|
-0.05
|
Immunosuppressants
|
4.6
|
0
|
-0.31
|
|
Renal impairment
|
35.4
|
23.9
|
-0.25
|
Lipid modifying agents
|
47.6
|
0
|
-1.35
|
|
Rheumatoid arthritis
|
9.2
|
6.3
|
-0.11
|
Opioids
|
27.7
|
0
|
-0.88
|
|
Schizophrenia
|
8.0
|
4.0
|
-0.17
|
Psycholeptics
|
38.4
|
0
|
-1.12
|
|
Ulcerative colitis
|
0.6
|
0.3
|
-0.04
|
Psychostimulants, agents used for adhd and nootropics
|
11.2
|
0
|
-0.50
|
|
Urinary tract infectious disease
|
28.7
|
18.4
|
-0.24
|
|
|
|
|
## Top drugs and conditions for DEC ##
|
drugs_180_days
|
n_180_days
|
|
beta blocking agents
|
156
|
|
antithrombotic agents
|
116
|
|
cardiovascular system
|
100
|
|
alimentary tract and metabolism
|
96
|
|
nervous system
|
95
|
|
antiepileptics
|
88
|
|
respiratory system
|
84
|
|
lipid modifying agents
|
82
|
|
lipid modifying agents, plain
|
82
|
|
agents acting on the renin-angiotensin system
|
78
|
|
analgesics
|
76
|
|
hmg coa reductase inhibitors
|
76
|
|
diuretics
|
75
|
|
psychoanaleptics
|
73
|
|
antihistamines for systemic use
|
70
|
|
sensory organs
|
70
|
|
antiinfectives for systemic use
|
69
|
|
blood and blood forming organs
|
69
|
|
ophthalmologicals
|
69
|
|
antidepressants
|
68
|
|
systemic hormonal preparations, excl. sex hormones and insulins
|
68
|
|
drugs used in diabetes
|
67
|
|
ace inhibitors, plain
|
66
|
|
ace inhibitors, plain
|
66
|
|
all other therapeutic products
|
66
|
|
cond_180_days
|
n_180_days
|
|
arthropathy
|
85
|
|
inflammation of specific body systems
|
84
|
|
heart disease
|
83
|
|
inflammation of specific body organs
|
77
|
|
pain
|
76
|
|
diabetes mellitus
|
74
|
|
pain finding at anatomical site
|
74
|
|
vascular disorder
|
70
|
|
measurement finding outside reference range
|
69
|
|
type 2 diabetes mellitus
|
69
|
|
pain of truncal structure
|
67
|
|
soft tissue lesion
|
66
|
|
degenerative disorder of musculoskeletal system
|
63
|
|
osteoarthritis
|
63
|
|
neoplastic disease
|
59
|
|
musculoskeletal and connective tissue disorder
|
56
|
|
abnormal blood cell count
|
55
|
|
cardiac arrhythmia
|
55
|
|
measurement finding below reference range
|
54
|
|
anemia
|
53
|
|
cytopenia
|
53
|
|
erythropenia
|
53
|
|
hemoglobin level outside reference range
|
53
|
|
hemoglobin low
|
53
|
|
rbc count abnormal
|
53
|